Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.
The approval comes after a late stage trial for its cancer therapy reached its primary endpoint in patients with brain metastases resulting from lung cancer.
Optune Lua is a portable device that produces alternating electric fields known as tumor treating fields, which are delivered through non-invasive, wearable arrays.
Novocure's Chinese partner Zai Lab (ZLAB) is down 2% premarket.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.